Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001214659-24-016740
Filing Date
2024-09-26
Accepted
2024-09-26 08:42:11
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 v9232406k.htm   iXBRL 6-K 839394
7 GRAPHIC ex99_1rdchart.jpg GRAPHIC 73894
  Complete submission text file 0001214659-24-016740.txt   4609957

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bdrx-20240630.xsd EX-101.SCH 54181
3 XBRL CALCULATION FILE bdrx-20240630_cal.xml EX-101.CAL 47807
4 XBRL DEFINITION FILE bdrx-20240630_def.xml EX-101.DEF 103626
5 XBRL LABEL FILE bdrx-20240630_lab.xml EX-101.LAB 232829
6 XBRL PRESENTATION FILE bdrx-20240630_pre.xml EX-101.PRE 203913
64 EXTRACTED XBRL INSTANCE DOCUMENT v9232406k_htm.xml XML 992534
Mailing Address 1 CASPIAN POINT CASPIAN WAY CARDIFF X0 CF10 4DQ
Business Address 1 CASPIAN POINT CASPIAN WAY CARDIFF X0 CF10 4DQ 44 (0)1235 888300
Biodexa Pharmaceuticals Plc (Filer) CIK: 0001643918 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37652 | Film No.: 241326249
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)